Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Mingyue Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0002-1817-0748; OpenAlex author ID A5102948252. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Co-author DOI 10.1038/s41388-025-03530-w↗
  2. Novel insight and perspectives of nanoparticle-mediated gene delivery and immune-modulating therapies for pancreatic cancer. Co-author DOI 10.1186/s12951-024-02975-7↗
  3. Loss of Heterozygosity for Kras G12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF-2α-c-Myc-Regulated Glutamine Metabolism. Co-author DOI 10.3390/ijms23126697↗
  4. Loss of heterozygosity for Kras G12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbrc.2020.03.137↗
  5. CircRHOT1 mediated cell proliferation, apoptosis and invasion of pancreatic cancer cells by sponging miR-125a-3p. Co-author DOI 10.1111/jcmm.15572↗
  6. Long non-coding RNA HOTAIR promotes cancer cell energy metabolism in pancreatic adenocarcinoma by upregulating hexokinase-2. First author DOI 10.3892/ol.2019.10551↗
  7. AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis. Co-author DOI 10.7150/jca.28299↗
  8. KrasG12D-LOH promotes malignant biological behavior and energy metabolism of pancreatic ductal adenocarcinoma cells through the mTOR signaling pathway. Co-author DOI 10.4149/neo_2018_170224n142↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bo Kong · 6 shared papers, 2018–2022 · strength 0.67
  2. Peilin Huang · 6 shared papers, 2018–2022 · strength 0.67
  3. Yu Ma · 5 shared papers, 2019–2022 · strength 0.60
  4. Sunkai Ling · 5 shared papers, 2018–2022 · strength 0.58
  5. Zipeng Lu · 2 shared papers, 2020–2025 · strength 0.27
  6. Kuirong Jiang · 2 shared papers, 2020–2025 · strength 0.27
  7. Xiaoping Zou · 2 shared papers, 2020–2025 · strength 0.27
  8. Xinqiao Wang · 1 shared paper, 2024 · strength 0.24
  9. Zhenhua Li · 1 shared paper, 2024 · strength 0.24
  10. Hui Liu · 1 shared paper, 2022 · strength 0.17
  11. Xuetian Qian · 1 shared paper, 2025 · strength 0.16
  12. Chao Fang · 1 shared paper, 2025 · strength 0.16
  13. Yifeng Sun · 1 shared paper, 2025 · strength 0.16
  14. Chao Li · 1 shared paper, 2025 · strength 0.16
  15. Susanne Roth · 1 shared paper, 2025 · strength 0.16
  16. Qi Zhang · 1 shared paper, 2025 · strength 0.16
  17. Hongzhen Li · 1 shared paper, 2025 · strength 0.16
  18. André L. Mihaljević · 1 shared paper, 2025 · strength 0.16
  19. Zhiheng Zhang · 1 shared paper, 2025 · strength 0.16
  20. Bo Kong · 1 shared paper, 2025 · strength 0.16
  21. Shuang Nie · 1 shared paper, 2025 · strength 0.16
  22. Christoph W. Michalski · 1 shared paper, 2025 · strength 0.16
  23. Helmut Friess · 1 shared paper, 2025 · strength 0.16
  24. Jorg H. Kleeff · 1 shared paper, 2025 · strength 0.16
  25. Christoph Kahlert · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.